logo
Future plans: Villages set for urban makeover under MMRDA blueprint; Rs 325 crore road project underway

Future plans: Villages set for urban makeover under MMRDA blueprint; Rs 325 crore road project underway

Time of India24-06-2025
MMRDA has begun preparing a Development Plan (DP) for Alibaug and parts of Pen, Panvel and Khalapur — areas now integrated into the Mumbai Metropolitan Region (MMR). The move aims to transform the largely rural belt into an urban extension of Mumbai, with industrial clusters, residential zones, and tourism infrastructure.
A major highlight is a Rs 325-crore road improvement project across 10 villages, with 10 major stretches set for concretisation. Work worth Rs 251 crore under three packages is already tendered, with a completion timeline of 24 months.
While demographic surveys and infrastructure studies are ongoing, the draft DP will be released for public suggestions and objections. Following are
MMRDA's
responses to a
TOI
questionnaire:
■ What prompted the inclusion of parts of Alibaug, Pen, Panvel, and Khalapur in MMRDA's planning area?
Alibaug, Pen, Panvel and Khalapur were already partly included in MMR (Mumbai Metropolitan Region).
Considering development potential of the talukas and influence of MMR, remaining parts were included on Sept 9, 2019. To channelize development, a Development Plan was essential. Therefore, Urban Development Department appointed MMRDA as Special Planning Authority in MMR's Extended Notified Area.
■ How will this benefit the residents?
The Development Plan (DP) will enable organised development and encourage industrial, residential and commercial, recreational and employment generating activities in the sub-region.
■ Are development control regulations ready for the region?
The Unified Development Control and Promotion Regulations are applicable for the area. The DP being prepared by MMRDA is at its early stage, the draft will be ready for publication in due course.
■ Do you see Alibaug as a prospective industrial zone or tourist zone or an extended suburb of Mumbai?
Alibaug taluka is now an integral part of the metropolitan region as an extended suburb of Mumbai via sea route. It is an established tourist destination. MMRDA envisages its development into an upcoming urbanised area with secondary and tertiary industries, residential and tourism belts.
■ What will be the status of agriculture in the area?
Land suitable for agriculture and already under cultivation will be maintained.
■ What kind of expansion is planned in terms of water
supply, garbage management, transport, and electricity for Alibaug?
Outside Alibaug council limit, the rest of the taluka is rural. The Draft DP will consider these aspects. A study of infrastructure in rural areas is underway to plan for balanced development.

Are there numerical projections for population for the region?
Demographic data collection and projections are part of the study for the ongoing Draft DP.
■ Who will clear the big projects?
The DP is being prepared in consultation with the Town Planning department. Data of physical and social infrastructure, industries, demography etc. is being collected.
■ Has MMRDA engaged with local stakeholders, panchayats, and residents regarding development in the region?
Draft DP once prepared, will be published for inspection and providing suggestions. Public consultation will be carried out.
10 villages in alibaug identified for road development
Vave | Beloshi | Mahajne | Mahan | Phansapur | Gaychole | Katalpada | Awas Phata | Bhonang-Talavali | Chowl
Timeline for completion of 325-cr road project
:
For work totalling 251 cr of 325 cr, construction period is 24 months (including monsoon)
Poynad Growth Center to impact Alibaug?
Poynad Junction Growth Center was notified in Final Regional Plan 2016-36. Significant development potential is seen in this area in Alibaug taluka. But MMRDA is not Planning Authority for this area.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Football federation confirms ISL on hold, awaits top court order to decide fate
Football federation confirms ISL on hold, awaits top court order to decide fate

India Today

timean hour ago

  • India Today

Football federation confirms ISL on hold, awaits top court order to decide fate

The All India Football Federation (AIFF) has officially confirmed that the 2025–26 Indian Super League (ISL) season is on hold — at least for now. In a statement released on July 12, the AIFF said that the current situation is under legal review, and a final decision on whether the ISL will go ahead this season will depend on the Supreme Court's fans had already seen reports of uncertainty around the ISL, the latest update now confirms that planning for the next season is on pause — and the root of the issue lies in the long-standing Master Rights Agreement (MRA) between AIFF and Football Sports Development Limited (FSDL), which runs the Statement #IndianFootball Indian Football Team (@IndianFootball) July 12, 2025"The AIFF has taken note of the communication issued pertaining to the Indian Super League (ISL), by our partners Football Sports Development Limited (FSDL), stating their inability to proceed with the forthcoming season of the ISL in the absence of clarity on FSDL's continuing rights under a renewed contractual framework," AIFF wrote in their statement. "Consequently, based on legal advice, discussions between the AIFF and FSDL have been put on hold... The AIFF recognises the importance of the ISL to clubs, players, officials, and fans... While the disruption is challenging, AIFF respects the law and the Supreme Court's direction... All efforts will be made to ensure ISL's continuity in the best interest of Indian football," the statement the AIFF's commercial partner since 2010, has been handling everything from managing and broadcasting to marketing Indian football under a 15-year deal that wraps up in December 2025. As part of the agreement, FSDL pays AIFF Rs 50 crore annually to oversee properties like the national team and the Indian Super with the deal nearing its end and no new contract in place, FSDL informed ISL clubs that it wouldn't be possible to properly plan or execute the 2025–26 season without clarity on what happens next. In other words — they can't move forward without a clear find a way out, FSDL has reportedly suggested a new structure: a holding company to run the ISL. Under this model, the clubs would hold a 60% stake, FSDL would retain 26%, and the remaining 14% would go to AIFF. It's a big shift — but for now, it's still just a proposal, with talks things remain uncertain, AIFF has reassured fans that all parties are working together behind the scenes to find a solution. The final call, though, depends on the Supreme Court's for now, Indian football's biggest league is on pause — stuck in a waiting game, with hopes high for a return soon.- EndsMust Watch

Delhi University hikes fees for MBA, PHD programmes and other courses; check key changes
Delhi University hikes fees for MBA, PHD programmes and other courses; check key changes

Time of India

timean hour ago

  • Time of India

Delhi University hikes fees for MBA, PHD programmes and other courses; check key changes

Delhi University has steadily hiked student fees over the past three years, with several key components seeing sharp increases since 2022. The trend continues in the 2025-26 academic session, where some components have seen hikes of over 20%—more than double the university's stated annual fee hike policy of 10%, reported TOI. The University Development Fund has risen by nearly 67%, while the University Facilities and Services Charges have soared by 200%. The Economically Weaker Section (EWS) Welfare Fund has also gone up by 150%, pointing to a consistent upward trend in fee structures. This year, the University Development Fund jumped from Rs 1,200 to Rs 1,500, a 25% increase. The University Facilities and Services Charges were raised from Rs 1,250 to Rs 1,500—a 20% hike. Meanwhile, the EWS Welfare Fund increased from Rs 200 to Rs 250, also marking a 25% rise in just one year. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like She is just 10 years old! She deserves to live a normal life Donate For Health Donate Now Undo The University Development Fund has grown from Rs 900 in 2022 to Rs 1,000 in 2023, then Rs 1,200 in 2024, and now Rs 1,500 in 2025. Similarly, the Facilities Charges increased from Rs 500 in 2022 to Rs 1,000 in 2023, Rs 1,250 in 2024, and Rs 1,500 this year. The Welfare Fund began at Rs 100 in 2022, rose to Rs 150 in 2023, Rs 200 in 2024, and now stands at Rs 250. These consistent hikes were approved by the vice-chancellor using emergency powers, with the notification on April 3. There was no immediate response from VC Yogesh Singh on the revision. Live Events What are key changes? Delhi University has revised the total annual fees for various programmes for the 2025–26 academic session, with amounts varying by stream and course. For undergraduate and postgraduate students, standard fees now range from Rs 8,000 to over Rs 20,000. The BEd and MEd programmes are priced at Rs 8,931 and Rs 9,046, respectively. Law courses like LLB and LLM cost Rs 8,087. On the higher end, technical programmes such as MCA and MSc Computer Science are priced at Rs 23,007 and Rs 22,887. Commerce students will pay Rs 16,900, while the MA in Social Work comes in at Rs 21,901. MBA fees vary widely, with the International Business (IB) and Human Resource Development (HRD) streams costing Rs 52,279, and the full-time Executive MBA priced at Rs 60,818. PhD candidates will also pay Rs 8,087 annually. The continuous rise in fees has triggered concern among both students and faculty, with many questioning the affordability of higher education at the university.

India pharma, healthcare revenue to grow steadily in Q1FY26E; EBITDA margins under pressure: Report
India pharma, healthcare revenue to grow steadily in Q1FY26E; EBITDA margins under pressure: Report

Time of India

timean hour ago

  • Time of India

India pharma, healthcare revenue to grow steadily in Q1FY26E; EBITDA margins under pressure: Report

Indian pharma and healthcare sector will witness steady revenue growth in the first quarter of the Financial Year 2026 (Q1FY26E), but concerns loom as EBITDA margins are expected to decline amid rising input costs and pricing pressures, according to a report by HDFC Securities. The report added that the pharma sector firms studied by it may witness a 11 per cent year-on-year (YoY) sales growth, driven by an 11 per cent YoY increase in the India business along with 2 per cent QoQ growth in US sales (+2 per cent YoY). The EBITDA, which stands for Earnings Before Interest, Taxes, Depreciation, and Amortization, is a financial metric used to assess a company's profitability and operational efficiency. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 이 게임은 대부분의 TV 프로그램보다 더 재미있어요 – 게다가 무료예요. Raid: Shadow Legends 플레이하기 Undo The report stated that EBITDA margins for the pharma segment are expected to decrease by 42bps YoY, driven by price erosion in the US and an expected increase in research and development (R&D). The hospital business is projected to grow by 15 per cent YoY, as muted occupancy will be partly supported by steady ARPOB, or Average Revenue Per Occupied Bed, which is a key performance indicator used in the healthcare industry to assess a hospital's financial performance. Live Events India's pharmaceutical market for FY 2023-24 is valued at USD 50 billion, with domestic consumption valued at USD 23.5 billion and exports valued at USD 26.5 billion. The domestic pharma industry is considered to be the world's third-largest by volume and 14th in terms of value of production. With an extremely diversified product base covering generic drugs, bulk drugs, over-the-counter drugs, vaccines, biosimilars, and biologics, the Indian pharmaceutical industry has a strong presence at the global level. According to National Accounts Statistics 2024, published by the Ministry of Statistics and Programme Implementation, total output for industry, i.e., Pharmaceuticals, medicinal and botanical products, is Rs. 4,56,246 crores for FY 2022-23 at constant prices, of which value added is Rs 1,75,583 crores.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store